CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants
Year: 2024
Type: article
Study design: Observational Study
Abstract: Variants in GBA1 result in dysregulated sphingolipids. We investigated five CSF d18:1 sphingolipid species in a longitudinal multicenter cohort comprising people with Parkinson's Disease and Dementia with Lewy bodies with and without GBA1 variants and healthy controls. We found no increase of sphingolipid species in heterozygous GBA1 variant participants and no effect on development of cognitive impairment. Thus, CSF d18:1 sphingolipids are not suitable as state markers in Parkinson's Disease.
Source: npj Parkinson s Disease
Institutions: German Center for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, University of Pavia, Biomedical Research Networking Center on Neurodegenerative Diseases, Vall d'Hebron Institut de Recerca, Aligning Science Across Parkinson's, Karolinska Institutet
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,590
Awards: G2076520454, Proyecto VHIP-GBA (Vall d’Hebron Iniciative for Parkinson associated to GBA): desde la recolección de muestras biológicas a los estudios translacionales y terapéuticos., El eje cerebro-periferia en pacientes con enfermedad de Parkinson: desde la fisiopatología hasta los biomarcadores y los enfoques terapéuticos, G6113104723
OpenAlex ID: W4403729268